SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,042-1.2%Dec 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Glenn Petersen who wrote (576)8/5/2020 9:47:01 AM
From: Moonray2 Recommendations

Recommended By
Glenn Petersen
Lance Bredvold

   of 642
 
U.S. begins trials of Eli Lilly’s antibody drug
Berkeley Lovelace Jr

The National Institutes of Health is starting two trials for
an experimental antibody drug to see if it can work as a
safe and effective treatment in Covid-19 patients.

The trials, called ACTIV-2 and ACTIV-3, will look at Eli Lilly’s
experimental treatment known as LY-CoV555, which is being
developed in partnership with Canadian biotech AbCellera.
The first trial will test the treatment on people with mild to
moderate Covid-19 symptoms who have not been hospitalized,
while the second trial will look at patients who have been
hospitalized.

The announcement comes a day after Eli Lilly said it began
phase three trial testing to see whether the treatment can
prevent the spread of coronavirus in residents and staff at nursing
homes. Eli Lilly’s drug is part of a class of treatments known as
monoclonal antibodies, which are made to act as immune cells.

o~~~ O
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News